Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Related Articles by Review for PubMed (Select 10746426)

1.

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ.

Aging (Milano). 2000 Feb;12(1):1-12.

PMID:
10746426
2.

Once-monthly dosing: an effective step forward.

Reid DM.

Bone. 2006 Apr;38(4 Suppl 1):S18-22. Epub 2006 Mar 13. Review.

PMID:
16533625
3.
4.

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P.

Dan Med Bull. 2002 Feb;49(1):1-18. Review.

PMID:
11894721
5.

Weekly administration of alendronate: rationale and plan for clinical assessment.

Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates J.

Clin Ther. 2000 Jan;22(1):15-28. Review.

PMID:
10688387
6.

Beyond daily dosing: clinical experience.

Cooper C.

Bone. 2006 Apr;38(4 Suppl 1):S13-7. Epub 2006 Mar 7. Review.

PMID:
16520105
7.

The clinical tolerability profile of alendronate.

Watts N, Freedholm D, Daifotis A.

Int J Clin Pract Suppl. 1999 Apr;101:51-61. Review.

PMID:
12669741
8.

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

Epstein S, Jeglitsch M, McCloskey E.

Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review.

PMID:
19835464
9.

Once weekly alendronate.

Sambrook P.

Drugs Today (Barc). 2003 May;39(5):339-46. Review.

PMID:
12861347
10.

An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women.

Hirsch LJ, Pryor-Tillotson S.

Ann Ital Med Int. 1995 Oct;10 Suppl:22S-28S. Review.

PMID:
8562261
12.

[Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].

Buffo L, Rossini M, Buoncristiano A, Girardello S, Zamberlan N, Diani F, Adami S.

Minerva Ginecol. 1996 Jun;48(6):263-72. Review. Italian.

PMID:
8927288
13.
14.

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD.

Osteoporos Int. 2006 Feb;17(2):159-66. Epub 2005 Jun 14. Review.

PMID:
15959614
15.
16.

Alendronate: an update of its use in osteoporosis.

Sharpe M, Noble S, Spencer CM.

Drugs. 2001;61(7):999-1039. Review.

PMID:
11434454
17.

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.

Moro-Alvarez MJ, Díaz-Curiel M.

Clin Interv Aging. 2008;3(2):227-32. Review.

19.
20.

The role of zoledronic acid in the management of osteoporosis.

Maricic M.

Clin Rheumatol. 2010 Oct;29(10):1079-84. doi: 10.1007/s10067-010-1486-3. Epub 2010 Jun 11. Review.

PMID:
20544246
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk